Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of semaglutide 2.4 mg once weekly in overweight or obese adults with type 2 diabetes
2017-003414-10Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing Semaglutide 2.4 mg once weekly with Placebo once weekly (2 arms). Primary endpoint: Primary body weight endpoints. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003414-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003414-10.